Esomeprazole (sodium) (Standard)

Esomeprazole (sodium) (Standard) is the analytical standard of Esomeprazole (sodium) . This product is intended for research and analytical applications. Esomeprazole sodium ((S) -Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H+-ATPases[4]. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research[1][2][3].

Product Specifications

CAS Number

[161796-78-7]

Product Name Alternative

(S) -Omeprazole (sodium) (Standard) ; (-) -Omeprazole (sodium) (Standard)

UNSPSC

12352005

Target

Bacterial; Proton Pump; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel; Others

Field of Research

Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/esomeprazole-sodium-standard.html

Smiles

O=[S@](C1=NC2=CC(OC)=CC=C2N1[Na])CC3=NC=C(C)C(OC)=C3C

Molecular Formula

C17H18N3NaO3S

Molecular Weight

367.40

References & Citations

[1]Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17 (3) :439-46.|[2]Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.|[3]Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59 (14) :1333-9.|[4]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1322-1330.